A new cancer treatment is making waves for its impressive breakthroughs in the treatment of haematological malignancies. In this issue of HealthNews, we take a look at the basics of CAR T-cell Therapy and how patients will benefit. What is CAR T-cell Therapy? Chimer...
[4]Xie B, Li Z, Zhou J, Wang W. Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. Cancers (Basel). 2022 Jun 30;14(13):3230. [5]Vincent RL, Gurbat...
近日,来自美国德州大学MD Anderson癌症中心的Hong教授团队在Nature Medicine上发表题为Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial的文章,报道了afami-cel治疗包括滑膜肉瘤、卵巢癌、头颈癌等多种HLA-A*02+ /MAGE-A4+复发/难治转移性实体瘤的I期多中心剂量...
Learn more about T-cell transduction CAR T-cell therapy: the latest weapon in the fight against cancer Read our blog post examining how CAR T-cell therapies for blood cancers show promise for a safer, targeted, and more effective cancer treatment. ...
1.Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. Cancers (Basel).2022 Jul; 14(13): 3230. 识别微信二维码,添加抗体圈小编,符合条件者即可加入抗体圈微信群!
[7]Hu D, Chen L, Yan D, Dong W, Chen M, Niu S, Wang S, Zhang J, Nie X, Fang Y. Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials. Front Pha...
参考资料：[1]2024 SITC:595 A phase I clinical trial evaluating the safety and preliminary efficacy of PAP CAR-T cells for the treatment of desmoplasia-resistant prostate cancer.[2]2024 SITC:340 Efficacy and safety of conditionally-activated CAR-T cells against gastrointestinal tumors.[3]2024...
[8] Pasquini Marcelo C,Locke Frederick L. Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US).Blood,2019. ...
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous https://www.fiercepharma.com/pharma/fda-investigates-serious-risk-secondary-cancer-following-car-t-therapy-treatment...
6.Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review :: Adaptimmune (ADAP) 7.Autologous T cell therapy for MAGE-A4+ solid cancers...